Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On June 18, 2025, Imunon, Inc. (IMNN) announced the presentation of positive translational data from the Phase 2 OVATION 2 study of IMNN-001 at the ESMO Gynaecological Cancers Congress 2025.</li><li>The translational data fully complement the overall survival results from the OVATION 2 trial and further validate the use of IL-12 as an immune activator in patients with newly diagnosed ovarian cancer.</li><li>Results presented at ESMO showed substantial localized increases in IL-12, interferon gamma (IFN-?), and tumor necrosis factor-alpha (TNF-?) while having limited systemic exposure.</li></ul>

On June 18, 2025, Imunon, Inc. (IMNN) announced the presentation of positive translational data from the Phase 2 OVATION 2 study of IMNN-001 at the ESMO Gynaecological Cancers Congress 2025.The translational data fully complement the overall survival results from the OVATION 2 trial and further validate the use of IL-12 as an immune activator in patients with newly diagnosed ovarian cancer.Results presented at ESMO showed substantial localized increases in IL-12, interferon gamma (IFN-?), and tumor necrosis factor-alpha (TNF-?) while having limited systemic exposure.

IMNN: Translational Data from OVATION 2 Presented 